Skip Navigation

Europace 2003 5(4):391-395; doi:10.1016/S1099-5129(03)00077-1
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mitchell, A. R. J.
Right arrow Articles by Sulke, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mitchell, A. R. J.
Right arrow Articles by Sulke, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Diazepam or midazolam for external DC cardioversion (The DORM Study)

A. R. J. Mitchell, S. Chalil, L. Boodhoo, G. Bordoli, N. Patel and N. Sulke

The Department of Cardiology, Eastbourne General Hospital Eastbourne, UK

AIMS: To compare the clinical efficacy and tolerability of two intravenous sedatives for physician-led DC cardioversion of atrial arrhythmias.

METHODS AND RESULTS: One hundred and forty-one patients attending for elective DC cardioversion of atrial arrhythmias were randomized to intravenous midazolam or diazepam. Sedation was administered using titration protocols. Procedure times, operator satisfaction scores and adverse events were documented. The patients' immediate, 24- and 48-h recall and awareness of after-effects were obtained from questionnaires. Seventy-one patients received midazolam (mean 12.5 mg) and 70 patients received diazepam (mean 28.1 mg). There were 16 minor adverse events with midazolam (20% hypotension, 3% oxygen desaturation) and nine with diazepam (7% hypotension, 6% required additional analgesia), P=0.14. There were no major adverse events. Sedation time was 5.0±3.4 min for midazolam and 6.5±3.4 min for diazepam (P=0.0016). Patients awoke 77±46 min post-sedation with midazolam and 39±24 min with diazepam (P<0.0001). There was no recall of the procedure at 48 h and no difference in awareness of after-effects between the two groups at 24 or 48 h, P=ns.

CONCLUSION: Physician-led cardioversion of atrial arrhythmias using intravenous sedation is effective and well tolerated. Sedation with diazepam was associated with fewer minor adverse events and a quicker recovery time than midazolam.

Key Words: Atrial fibrillation, cardioversion, sedation, diazepam, midazolam

Correspondence: Andrew R. J. Mitchell, Department of Cardiac Rhythm Management, John Radcliffe Hospital, Oxford, OX3 9DU, U.K. Tel.: +44-1865-220981; Fax: +44-1865-221432. E-mail: mitcharj{at}doctors.org.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
N Sulke, F Sayers, G Y H Lip, and on behalf of the Guideline Development Group for t
Rhythm control and cardioversion
Heart, January 1, 2007; 93(1): 29 - 34.
[Full Text] [PDF]

Home page
 Emerg. Med. J.Home page
J. Wood and C. Ferguson
Procedural sedation for cardioversion
Emerg. Med. J., December 1, 2006; 23(12): 932 - 934.
[Full Text] [PDF]

Home page
 HeartHome page
L Boodhoo, G Bordoli, A R Mitchell, G Lloyd, N Sulke, and N Patel
The safety and effectiveness of a nurse led cardioversion service under sedation
Heart, December 1, 2004; 90(12): 1443 - 1446.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.